What did @naturalkaos actually say?
The creator presented three peptides, GHK-Cu, BPC-157, and TB-500, as a coordinated stack that works "on a cellular level" to support skin health and whole-body recovery. They described GHK-Cu as resetting gene expression "to a more youthful state," BPC-157 as a body protection compound with gut healing and joint support properties, and TB-500 as a synthetic peptide that promotes cell migration and tissue regeneration. The framing was mechanistic and confident, stopping just short of direct disease claims, though phrases like "internal environment that supports skin health" do a lot of heavy lifting without much qualification. To the creator's credit, they used cautious language like "may improve" and "believed to create" in places, which is more than most TikTok peptide content manages.
Does the science back this up?
Partially, and the degree varies significantly by peptide. GHK-Cu has the strongest published record of the three. BPC-157 has interesting preclinical data but almost no human trial evidence. TB-500 is the weakest link here, and the creator's description contains a factual error worth flagging.
GHK-Cu research is genuinely interesting. Pickart and Margolina (2018, Cosmetics) documented its role in upregulating collagen and elastin synthesis, and Gorouhi and Maibach (2009, International Journal of Cosmetic Science) reviewed topical copper peptide evidence for skin remodeling. The "resetting gene expression" claim has some basis in Pickart's work showing GHK-Cu modulates over 4,000 genes, though calling that a reset to a "youthful state" is a stretch that overstates what the data shows.
BPC-157's wound healing and angiogenesis properties come largely from rat models. Seiwerth et al. (2018, Current Pharmaceutical Design) reviewed its tissue repair effects, but the jump from rodent gastric ulcer studies to "gut healing" claims in humans is a significant leap. There are no large randomized controlled trials in humans.
TB-500 is where things get shaky. The creator called it a synthetic version of "thiomyosine beta-4," but the actual peptide is thymosin beta-4, a different name entirely. This is not a trivial error.
What did they get wrong (or right)?
The error on TB-500 stands out. The peptide is thymosin beta-4, not thiomyosine beta-4. These sound similar but the nomenclature matters when people are researching what they might be putting in their bodies. TB-500 is a synthetic fragment of thymosin beta-4, specifically the actin-binding domain, not a direct synthetic version of the full protein, so even the structural description is imprecise.
The GHK-Cu section was mostly accurate. Describing it as "naturally found in the human body" is correct, it appears in plasma, saliva, and urine at declining levels with age. The gene expression angle is legitimate science, though "resetting to a more youthful state" is marketing language dressed up as mechanism.
BPC-157's description as a "peptide fragment derived from gastric proteins" is accurate. Calling its properties "reported" rather than proven shows appropriate restraint. The angiogenesis claim is supported in preclinical literature. But presenting all three peptides as a coherent, evidence-based stack implies a level of clinical validation that simply does not exist for this combination.
What should you actually know?
None of these peptides are FDA-approved for the indications described. GHK-Cu is available in topical cosmetic products, and that is where most of its human-applicable evidence sits. BPC-157 and TB-500 are research chemicals when obtained outside a regulated clinical context. They are not approved drugs, and compounded versions vary significantly in purity and dosing accuracy.
The stack concept, the idea that combining peptides creates synergistic benefits, is not supported by clinical trial data. It is a hypothesis. Stack protocols circulating on TikTok are built on extrapolation from separate preclinical studies, not controlled combination trials in humans.
If you are considering peptide therapy, that conversation belongs with a licensed provider on a regulated platform, not in a comment section. The science is genuinely interesting, but "interesting preclinical data" and "proven human treatment" are not the same thing, and this video does not always make that distinction clear.